398 related articles for article (PubMed ID: 26058278)
1. Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
Kanchanaranya N; Rojdamrongratana D; Piyasoonthorn P
J Med Assoc Thai; 2015 May; 98(5):489-94. PubMed ID: 26058278
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients.
Ng DS; Kwok AK; Chan CW; Li WW
Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
6. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.
Chaudhary KM; Romero JM; Ezon I; Fastenberg DM; Deramo VA
Retina; 2013; 33(7):1407-16. PubMed ID: 23492945
[TBL] [Abstract][Full Text] [Related]
7. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
[TBL] [Abstract][Full Text] [Related]
9. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
[TBL] [Abstract][Full Text] [Related]
10. Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics.
Park Y; Kim KS; Park YH
J Ocul Pharmacol Ther; 2013 Dec; 29(10):900-5. PubMed ID: 24067061
[TBL] [Abstract][Full Text] [Related]
11. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
12. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Haddock LJ; Ramsey DJ; Young LH
Semin Ophthalmol; 2014; 29(5-6):257-62. PubMed ID: 25325851
[TBL] [Abstract][Full Text] [Related]
13. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.
Lyall DA; Tey A; Foot B; Roxburgh ST; Virdi M; Robertson C; MacEwen CJ
Eye (Lond); 2012 Dec; 26(12):1517-26. PubMed ID: 23060022
[TBL] [Abstract][Full Text] [Related]
14. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
[TBL] [Abstract][Full Text] [Related]
15. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
[TBL] [Abstract][Full Text] [Related]
16. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.
McCannel CA
Retina; 2011 Apr; 31(4):654-61. PubMed ID: 21330939
[TBL] [Abstract][Full Text] [Related]
18. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
[TBL] [Abstract][Full Text] [Related]
19. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection.
Artunay O; Yuzbasioglu E; Rasier R; Sengül A; Bahcecioglu H
Eye (Lond); 2009 Dec; 23(12):2187-93. PubMed ID: 19218994
[TBL] [Abstract][Full Text] [Related]
20. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]